Bone morphogenetic protein 2 regulates cell-cell communication by down-regulating connexin43 expression in luteinized human granulosa cells

Mol Hum Reprod. 2017 Mar 1;23(3):155-165. doi: 10.1093/molehr/gaw078.

Abstract

Study question: Does bone morphogenetic protein 2 (BMP2) regulate connexin43 (Cx43) and modulate cell-cell communication in luteinized human granulosa cells?

Summary answer: BMP2 decreases gap junction intercellular communication (GJIC) of luteinized human granulosa cells by down-regulating Cx43 expression through an activin receptor-like kinase (ALK)2/ALK3-mediated Sma- and Mad-related protein (SMAD)-dependent signaling pathway.

What is known already: BMP2 and its putative receptors are highly expressed in the human corpus luteum and are involved in the process of luteolysis. Cx43-coupled gap junctions play a critical role in the development and maintenance of corpus luteum.

Study design duration: This is a laboratory study conducted over a 1-year period. At least three independent experiments with three replicates were conducted and the experimental samples were compared with the appropriate vehicle controls for all of the inhibition-approach, concentration-dependent or time-course studies.

Participants/materials, setting, methods: SVOG cell line (immortalized human granulosa-lutein cells derived from in vitro fertilization patients in an academic research center) was used as the study model. The changes of Cx43 expression and levels of phosphorylated SMAD1/5/8 protein were evaluated after exposure to recombinant human BMP2. Real-time quantitative PCR and Western blot analysis were used to examine the specific mRNA and protein levels, respectively. The BMP/TGF-β type I receptor inhibitors (Dorsomorphin, DMH-1 and SB431542) and target depletion small interfering RNAs (ALK2, ALK3, ALK6 and SMAD4) were used to investigate the underlying molecular mechanisms. A scrape loading and dye transfer assay was used to evaluate the GJIC between the SVOG cells.

Main results and the role of chance: Treatment with BMP2 down-regulated the expression of Cx43 and decreased the GJIC activity, whereas it increased the phosphorylated SMAD1/5/8 protein in SVOG cells (P < 0.05). These biological effects were abolished by pre-treatment with the BMP type I receptor inhibitors, Dorsomorphin and DMH-1 (P < 0.05), but not SB431542. Additionally, the individual or concomitant small interfering RNA-mediated knockdown of ALK2 and ALK3, but not ALK6 attenuated the BMP2-induced increases in phosphorylated SMAD1/5/8 and down-regulation of Cx43 expression (P < 0.05). The knockdown of SMAD4 completely abolished the BMP2-induced down-regulation of Cx43 expression (P < 0.05).

Limitations reasons for caution: This experimental study was conducted in an in vitro cell culture system, and may not reflect a realistic intra-ovarian environment.

Wider implications of the findings: Our results suggested that BMP2 may be involved in the local modulation of cell-cell communication in the luteal phase. This study also represents the first comprehensive research of molecular mechanisms of BMP2 in the down-regulation Cx43 in luteinized human granulosa cells. Such data may provide valuable insights into ovarian physiology and benefit the development of potential therapeutic methods for patients suffering from luteal insufficiency.

Large scale data: N/A.

Study funding and competing interest(s): This research was supported by an operating grant from the China-Canadian Joint Health Research Initiative Grants Program to P.C.K. Leung and J.Z. Sheng. The authors declare no competing interest with the contents of this article.

Keywords: ALK; BMP2; SMAD; connexin43; luteinized human granulosa cells.

MeSH terms

  • Activin Receptors, Type I / genetics*
  • Activin Receptors, Type I / metabolism
  • Bone Morphogenetic Protein 2 / genetics
  • Bone Morphogenetic Protein 2 / metabolism
  • Bone Morphogenetic Protein 2 / pharmacology*
  • Cell Communication / drug effects*
  • Cell Line, Transformed
  • Connexin 43 / antagonists & inhibitors
  • Connexin 43 / genetics*
  • Connexin 43 / metabolism
  • Female
  • Gap Junctions / drug effects
  • Gap Junctions / metabolism
  • Gene Expression Regulation
  • Humans
  • Luteal Cells / cytology
  • Luteal Cells / drug effects*
  • Luteal Cells / metabolism
  • Phosphorylation / drug effects
  • Protein Isoforms / genetics
  • Protein Isoforms / metabolism
  • Pyrazoles / pharmacology
  • Pyrimidines / pharmacology
  • Quinolines / pharmacology
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / metabolism
  • Recombinant Proteins / genetics
  • Recombinant Proteins / metabolism
  • Signal Transduction
  • Smad1 Protein / antagonists & inhibitors
  • Smad1 Protein / genetics
  • Smad1 Protein / metabolism
  • Smad5 Protein / antagonists & inhibitors
  • Smad5 Protein / genetics
  • Smad5 Protein / metabolism
  • Smad8 Protein / antagonists & inhibitors
  • Smad8 Protein / genetics
  • Smad8 Protein / metabolism

Substances

  • BMP2 protein, human
  • Bone Morphogenetic Protein 2
  • Connexin 43
  • DMH1 compound
  • Protein Isoforms
  • Pyrazoles
  • Pyrimidines
  • Quinolines
  • RNA, Small Interfering
  • Recombinant Proteins
  • SMAD1 protein, human
  • SMAD5 protein, human
  • SMAD9 protein, human
  • Smad1 Protein
  • Smad5 Protein
  • Smad8 Protein
  • dorsomorphin
  • ACVR1 protein, human
  • Activin Receptors, Type I